Home > Insider Trading > Filing (0000947871-23-001190)

Filing Details

Accession Number:: 0000947871-23-001190
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-12-29 16:20:45
Reporting Period:: 2023-12-27

Accepted Time:: 2023-12-29 16:20:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1626199	Alpine Immune Sciences Inc.	ALPN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Alpine Immune Sciences, Inc. 188 East Blaine Street, Suite 200 Seattle WA 98102		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-12-27	162,576	$19.96	3,493,485	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-27	18,922	$19.96	406,609	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-28	26,872	$19.82	3,466,613	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-28	3,128	$19.82	403,481	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-28	1,195,683	$18.32	2,270,930	No	4	S	Indirect	See footnotes
Common Stock	Disposition	2023-12-28	139,166	$18.32	264,315	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes
No	4	S	Indirect	See footnotes

Footnotes

These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis.
Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.